Oxford Biomedica (OXB) investor relations material

Strategic transformation and market positioning

• Completed transition to a pure-play CDMO, scaling globally with revenues rising from £89.5m in FY23 to £170.9m in FY25 and projected £220–240m in FY26.

• Ranked as the 4th largest viral vector CDMO by market share, with a YoY revenue growth of ~30%, outpacing the 12% CGT market CAGR.

• Expanded manufacturing footprint in the US and Europe, including acquisitions in Durham, Lyon, and Strasbourg.

• Over 30 years of experience, with more than 1,000 batches delivered and 100+ successful audits.

• Diversified portfolio with 52 client programs, including major pharma and biotech clients.

Financial performance and outlook

• Revenue grew from £90m in FY23 to £169m in FY25, with EBITDA turning positive at £8.1m in FY25.

• Revenue backlog increased 36% YoY to £204m at end FY25, supporting future growth.

• FY26 revenue guidance of £220–240m, with 60% covered by contracted orders and EBITDA margin expected at ~10%.

• Targeting 25–30% annual revenue growth in 2027–28 and long-term EBITDA margins approaching 30%.

• Cash position strengthened to £96.9m at end FY25, supported by equity raise and new loan facility.

Operational capabilities and client services

• Provides end-to-end viral vector manufacturing for all clinical phases and vector types (AAV, LV, Adeno, MVA/Pox, others).

• Global network includes centers of excellence in the UK, US, and France, supporting development to commercial supply.

• Strong commercial track record, with >60% of FY25 revenue from late-phase projects.

• Flexible tech transfer, digitalization, and process innovation drive productivity and quality.

• ESG initiatives include a 40% reduction in GHG emissions since 2021 and increased renewable energy sourcing.